Burt Adelman, M'D'

1
Summit on Systems Biology 2007

• Burt Adelman, M.D.
• Executive Vice President, Portfolio Strategy
• 5 June 2007

2
RD Investments by Research-Based Pharmaceutical
Companies1984-2005
Total NMEs approved each year
Expenditures ( billions)
53
55 50 45 40 35 30 25 20 15 10 5 0
39.4
22
18
16.9
3.6
Year
Source FDA PhRMA Annual Survey, 2006
3
Probability of Success from First Human Dose to
Market by Therapeutic Area (based on NASs
entering phase 1994-99)

Probability of Success







PARAXELs Pharmaceutical RD Statistical
Sourcebook 2005/2006
4
The Value Equation

• Safety
• Efficacy
• Value

5
What we Should be Doing Together

• Understand human pathobiology
• Focus industry research efforts on making drugs
• Collaborate with the scientific community